ServiceNow (NOW) stock declined approximately -22% over the past 30 days, driven by analyst downgrades and concerns over AI disruption in software budgets. Over the past quarter, the stock fell around -34%, reflecting broader sector weakness and shifting enterprise spending priorities amid AI investments.

GE Vernova (GEV) stock surged +23% over the past 30 days, driven by analyst upgrades, European expansion deals including a Hungary MoU and SMR services agreement, and strong sector demand for power equipment. Over the past quarter, shares climbed +54%, fueled by robust Q4 2025 earnings beat, record orders and backlog growth, and momentum in gas power and electrification amid AI-driven electricity needs.

HUBB stock surged +15% over the past 30 days, driven by strong demand in data centers, utility infrastructure, and electrical solutions amid grid modernization trends. Over the past quarter, the stock rose +13%, supported by positive analyst upgrades and anticipation ahead of Q1 2026 earnings.

UBS stock surged +12% over the past 30 days, driven by a favorable Swiss court ruling dismissing a legacy Credit Suisse money-laundering case tied to Mozambique, reducing legal overhangs. Over the past quarter, the stock declined -12%, reflecting broader banking sector pressures from geopolitical tensions, elevated oil prices, and Middle East conflict risks impacting market sentiment.

ESLT stock rose +6% over the past 30 days, driven by a major $750 million contract for PULS rocket artillery systems with Greece and sustained defense sector momentum. Over the past quarter, shares surged +32%, propelled by record Q4 2025 earnings, a $28.1 billion order backlog, and heightened global demand for defense technologies.

CW stock rose approximately +12% over the last 30 days, driven by strong defense sector momentum and analyst price target increases. Over the past quarter, shares gained +15%, supported by robust Q4 2025 earnings beat, record backlog, and positive 2026 guidance.

PWR stock rose approximately +5% over the last 30 days amid volatile trading, driven by strong backlog growth and positive analyst sentiment. Over the past quarter, shares gained around +30%, fueled by robust Q4 2025 earnings beat and demand for infrastructure solutions.

NOC stock declined approximately -8% over the past 30 days amid profit-taking after a strong quarterly rally and mixed sector sentiment. Over the past quarter, shares rose +8%, driven by robust Q4 2025 earnings beat, record backlog, and defense contract wins.

Rio Tinto's half-year results for the six months ended June 30, 2026, are scheduled for release on July 29, 2026. Analysts expect continued strength in copper production from Oyu Tolgoi ramp-up, offsetting potential iron ore price volatility.

RIO stock rose +12% over the last 30 days, driven by strong copper production beats and interest in U. S.

VZ stock declined approximately -10% over the past 30 days amid analyst downgrades, profit-taking after a strong quarterly rally, and sector-wide pressures in telecommunications. Over the past quarter, the stock surged +23%, driven by robust Q4 2025 earnings beat, upbeat 2026 guidance, and strong subscriber growth including over 1 million net adds.

SYRE shares surged approximately 25% in Monday's session, with the stock rising from a previous close of $51.29 to approximately $64.11 intraday. The primary catalyst is a highly positive Phase 2 SKYLINE trial readout: SPY001 met its primary endpoint with a statistically significant 9.2-point reduction in Robart's Histopathology Index (RHI) score (p<0.0001) at Week 12 in moderate-to-severely active ulcerative colitis patients.

Shares of Revolution Medicines (RVMD) surged +37.33% in today's session, rising from a prior close of $96.43 to $132.43, with an intraday high of $135.81. The primary catalyst is a landmark Phase 3 clinical trial win: daraxonrasib nearly doubled median overall survival versus standard chemotherapy in second-line metastatic pancreatic ductal adenocarcinoma (PDAC)

LITE shares are trading down approximately 5% in Monday's session (April 13, 2026), from a prior close of $897.30 to roughly $852.44. The decline is driven primarily by broad market risk-off sentiment tied to geopolitical tensions and ongoing tariff uncertainty, with no company-specific negative catalyst.

ERAS shares declined approximately -12% intraday on Monday, April 13, 2026, pulling back sharply from a recent 52-week high of $18.20 reached on April 7. The selloff appears primarily driven by profit-taking and valuation pressure after a staggering ~1,497% rally over the past twelve months, with shares trading well above most pre-run analyst consensus targets.

Replimune Group (REPL) shares collapsed approximately 63.24% in premarket trading on Monday, April 13, 2026, falling from a Friday close of $4.76 to around $1.75. The primary catalyst is the FDA's second consecutive Complete Response Letter (CRL) issued April 10, 2026, rejecting the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.

Analysts expect Q1 2026 EPS of approximately $4.77-$4.85, up slightly from $4.65 in Q1 2025. Revenue consensus around $22.6B-$23.2B, reflecting 9.7%-4.5% year-over-year growth.

Morgan Stanley (MS) stock surged +15% over the past 30 days, driven by the launch of its low-cost Bitcoin ETF and positive analyst upgrades ahead of Q1 earnings. Over the past quarter, the stock is relatively flat at -1%, reflecting volatility from geopolitical tensions and private credit concerns offset by a strong rebound.

Goldman Sachs ( GS ) reports Q1 2026 earnings on April 13, with consensus EPS of $16.34 and revenue of $16.95 billion, signaling 16% EPS growth year-over-year. Morgan Stanley ( MS ) follows on April 15, expecting EPS of $3.02 and revenue of $19.71 billion, up 16% in EPS.

BAC stock rose approximately +11% over the past 30 days, rebounding from mid-March lows around $47 amid positive net interest income (NII, the difference between interest earned on loans and paid on deposits) guidance and analyst upgrades. Over the past quarter, the stock declined about -5%, reflecting earlier pressures from peak levels near $55 in January due to interest rate volatility and macroeconomic concerns.